OXTELLAR XR

LOE Approaching

oxcarbazepine

NDAORALTABLET, EXTENDED RELEASE
Approved
Oct 2012
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
16

Mechanism of Action

10-monohydroxy metabolite (MHD) of oxcarbazepine [see ]. The precise mechanism by which oxcarbazepine and MHD exert their antiseizure effect is unknown; however, in vitro electrophysiological studies indicate that they produce blockade of voltage-sensitive sodium channels, resulting in…

Pharmacologic Class:

Anti-epileptic Agent

Clinical Trials (5)

NCT03695094Phase 1Completed

A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil

Started Sep 2018
31 enrolled
Epilepsy
NCT02104661Phase 2Completed

Protective Role of Oxcarbazepine in Multiple Sclerosis

Started Oct 2014
30 enrolled
Multiple Sclerosis
NCT02098941N/AUnknown

Evaluate Retention Rate of Topiramate, Levetiracetam and Oxcarbazepine in a Long-term Epilepsy Treatment

Started Mar 2014
2,500 enrolled
Epilepsy
NCT01498822Phase 4Completed

Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy

Started Jun 2011
353 enrolled
Epilepsy
NCT00975715Phase 2/3Completed

Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures

Started Sep 2009
99 enrolled
Partial Onset Seizures

Loss of Exclusivity

LOE Date
Apr 13, 2027
13 months away
Patent Expiry
Apr 13, 2027

Patent Records (5)

Patent #ExpiryTypeUse Code
10220042
Apr 13, 2027
U-2501
11166960
Apr 13, 2027
Product
11896599
Apr 13, 2027
Product
7722898
Apr 13, 2027
Product
7910131
Apr 13, 2027
U-2041